STAT3 and central nervous system cancer: Interestingly, glioma tissue displayed an increase in pSTAT3 levels upon ITE+PD1 treatment, suggesting that IL-11 and IL-6 are likely not the primary regulators of STAT3 in this context and highlighting STAT3 as a potential target for combination therapy (Figure 5E).